Gastroparesis - Pipeline Insight, 2025

This “Gastroparesis - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 11+ pipeline drugs in Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Gastroparesis: Understanding

Gastroparesis: Overview

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of a mechanical obstruction. The most common known cause is diabetes, which can damage the nerves and muscles that regulate stomach contractions. Other potential causes include nerve injury, autoimmune disorders, neurological conditions, viral infections, and certain medications. In many cases, the underlying cause is unknown, and the condition is classified as idiopathic. Gastroparesis is more common in women and can lead to symptoms like nausea, vomiting, abdominal pain, malnutrition, and difficulty controlling blood sugar levels.

The epidemiology of gastroparesis varies across studies, but recent data provides a clearer picture. A population-based study in the UK estimated the standardized prevalence of diagnosed gastroparesis at 13.8 per 100,000 persons in 2016, with the incidence rising from 1.5 per 100,000 person-years in 2004 to 1.9 per 100,000 person-years in 2016. Another study in Israel found the prevalence of definite gastroparesis cases to be 1.5 per 100,000, with diabetes accounting for 17.2% of these cases. In the US, a recent study using health insurance data reported a prevalence of 268 per 100,000 adults, with the highest rates among those aged 65 and older. However, a population-based estimate suggests gastroparesis may affect up to 1.8% of the US population. Globally, a study found the overall prevalence of gastroparesis-like symptoms to be 0.9%, rising to 1.3% among diabetic individuals.

The most common symptoms of gastroparesis include vomiting, nausea, upper abdominal discomfort or pain, bloating, feeling full after only a few bites of food, and excessive burping or belching. Some people with gastroparesis also experience heartburn, poor appetite, and difficulty controlling blood sugar levels. The pain associated with gastroparesis is often described as dull or sharp in the upper belly area around the stomach or intestines. Certain medications like narcotics and antidepressants can also delay gastric emptying and exacerbate gastroparesis symptoms. In severe cases, gastroparesis can lead to complications like bacterial overgrowth, dehydration, intestinal blockages, malnutrition, and difficulty managing blood sugar.

The treatment of gastroparesis involves dietary changes, medications, endoscopic procedures, and surgical interventions. Dietary modifications include eating smaller meals, avoiding high-fiber/fat foods, and consuming liquids/pureed foods. Prokinetic drugs and antiemetics can stimulate gastric emptying and control nausea/vomiting. For severe cases, gastrostomy tubes, pyloromyotomy, gastric pacing, or pyloroplasty may be necessary. A multidisciplinary team approach is often required to optimize management and prevent complications like dehydration and electrolyte imbalances.

'Gastroparesis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroparesis pipeline landscape is provided which includes the disease overview and Gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Gastroparesis.

Gastroparesis Emerging Drugs Chapters

This segment of the Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastroparesis Emerging Drugs

Naronapride: Renexxion

Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for unmet GI indications in the upper and lower GI tract. In scientific studies, naronapride has been demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride is designed to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is indistinguishable from placebo. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Gastroparesis.

Gastroparesis: Therapeutic Assessment

This segment of the report provides insights about the different Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastroparesis

There are approx. 10+ key companies which are developing the therapies for Gastroparesis. The companies which have their Gastroparesis drug candidates in the most advanced stage, i.e. Phase II include, Renexxion.

Phases

The report covers around 11+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastroparesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroparesis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroparesis drugs.

Gastroparesis Report Insights

• Gastroparesis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastroparesis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastroparesis drugs?
• How many Gastroparesis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroparesis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastroparesis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastroparesis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Renexxion
• PTC Therapeutics
• CinRx Pharma
• RaQualia Pharma
• Processa Pharmaceuticals
• Millennium Pharmaceuticals

Key Products

• Naronapride
• CNSA-001
• CIN-102
• RQ-00000010
• PCS12852
• TAK-906 Maleate

This product will be delivered within 2 business days.